Patents by Inventor Robert Brian Jones

Robert Brian Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Medical treatment
    Publication number: 20040077730
    Abstract: A compound of formula I 1
    Type: Application
    Filed: August 15, 2003
    Publication date: April 22, 2004
    Inventors: Clifford James Bailey, Robert Brian Jones, Helen Christine Jackson
  • Medical treatment
    Patent number: 6617360
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: September 9, 2003
    Assignee: Knoll Aktiengesellschaft
    Inventors: Clifford James Bailey, Robert Brian Jones, Helen Christine Jackson
  • Substituted 3-benzylpyrazoles and their use as herbicides
    Patent number: 6451734
    Abstract: The present invention relates to novel substituted 3-benzylpyrazoles of the formula I
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: September 17, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Cyrill Zagar, Gerhard Hamprecht, Markus Menges, Olaf Menke, Peter Schäfer, Karl-Otto Westphalen, Ulf Misslitz, Helmut Walter, Robert Reinhard, Robert Brian Jones
  • Use of sibutramine analogues to prevent the development of diabetes
    Patent number: 6174925
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: January 16, 2001
    Assignee: Knoll Aktiengesellschaft
    Inventors: Clifford James Bailey, Robert Brian Jones, Helen Christine Jackson
  • Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications
    Patent number: 6133267
    Abstract: A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate) is used for inhibiting the formation of advanced glycosylation end-products, and for the treatment and/or prophylaxis of long-term complications associated with diabetes, such as atherosclerosis, nephropathy, neuropathy and retinopathy.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: October 17, 2000
    Assignee: Knoll Aktiengesellschaft
    Inventors: Annemarie Elizabeth Claire Merryman Simpson, Robert Brian Jones